Premium
Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?
Author(s) -
Pal Sumanta K.,
Figlin Robert A.
Publication year - 2014
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.28636
Subject(s) - ramucirumab , sunitinib , medicine , sorafenib , renal cell carcinoma , context (archaeology) , oncology , clear cell renal cell carcinoma , axitinib , cancer , hepatocellular carcinoma , paleontology , biology
The current editorial focuses on a phase 2 study evaluating ramucirumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior sunitinib and/or sorafenib therapy. The potential for further development is discussed in the context of the rapidly changing landscape of therapy for mRCC.